Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial

被引：2
|
作者：
Wulfkuhle, J. D.
Yau, C.
Wolf, D. M.
Gallagher, R. I.
Deng, J.
Brown-Swigart, L.
Hirst, G.
Rugo, H.
Olopade, O. I.
Esserman, L.
Berry, D.
van't Veer, L.
Petricoin, E. F.
机构：
[1] George Mason Univ, Manassas, VA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] QuantamLeap Healthcare Collaborat, Berkeley, CA USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Berry Consultants LLC, Austin, TX USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-07-48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-48
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy-Results from ACRIN 6657/I-SPY TRIAL
    Hylton, Nola M.
    Blume, Jeffrey D.
    Bernreuter, Wanda K.
    Pisano, Etta D.
    Rosen, Mark A.
    Morris, Elizabeth A.
    Weatherall, Paul T.
    Lehman, Constance D.
    Newstead, Gillian M.
    Polin, Sandra
    Marques, Helga S.
    Esserman, Laura J.
    Schnall, Mitchell D.
    RADIOLOGY, 2012, 263 (03) : 663 - 672
  • [32] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [33] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Melissa Krystel-Whittemore
    Jin Xu
    Edi Brogi
    Katia Ventura
    Sujata Patil
    Dara S. Ross
    Chau Dang
    Mark Robson
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2019, 177 : 61 - 66
  • [34] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Krystel-Whittemore, Melissa
    Xu, Jin
    Brogi, Edi
    Ventura, Katia
    Patil, Sujata
    Ross, Dara S.
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 61 - 66
  • [35] DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial.
    van't Veer, Laura
    Esserman, Laura
    Sanil, Ashish
    Glas, Annuska
    Severson, Tessa
    Linn, Sabine C.
    Swigart, Lamorna Brown
    Hirst, Gillian
    Olopade, Olufunmilayo I.
    Rugo, Hope S.
    Berry, Don
    Wolf, Denise M.
    Yau, Christina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.
    Thomas, Alexandra
    Clark, Amy Sanders
    Yau, Christina
    Wolf, Denise M.
    van ' T Veer, Laura
    Douglas, Emily H.
    Chien, Amy Jo
    Huppert, Laura Ann
    Rugo, Hope S.
    Shatsky, Rebecca Arielle
    Isaacs, Claudine
    Berry, Donald A.
    Yee, Douglas
    DeMichele, Angela
    Esserman, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.
    Yee, Douglas
    Shatsky, Rebecca Arielle
    Yau, Christina
    Wolf, Denise M.
    Nanda, Rita
    Van ' T Veer, Laura
    Berry, Donald A.
    DeMichele, Angela
    Esserman, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] HER2 Positivity, High Mitotic Rate, and Tumor Grade Are Associated With Pathologic Complete Response To Neoadjuvant Therapy in Breast Cancer
    Robinson, Brian
    O'Regan, Ruth
    Styblo, Toncred
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2015, 95 : 63A - 63A
  • [39] HER2 Positivity, High Mitotic Rate, and Tumor Grade Are Associated With Pathologic Complete Response To Neoadjuvant Therapy in Breast Cancer
    Robinson, Brian
    O'Regan, Ruth
    Styblo, Toncred
    Li, Xiaoxian
    MODERN PATHOLOGY, 2015, 28 : 63A - 63A
  • [40] DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
    Wolf, Denise M.
    Yau, Christina
    Sanil, Ashish
    Glas, Annuska
    Petricoin, Emanuel
    Wulfkuhle, Julia
    Severson, Tesa M.
    Linn, Sabine
    Brown-Swigart, Lamorna
    Hirst, Gillian
    Buxton, Meredith
    DeMichele, Angela
    Hylton, Nola
    Symmans, Fraser
    Yee, Doug
    Paoloni, Melissa
    Esserman, Laura
    Berry, Don
    Rugo, Hope
    Olopade, Olufunmilayo
    van t'Veer, Laura
    NPJ BREAST CANCER, 2017, 3
12345